HIV AIDS. Human immunodeficiency virus [HIV]
Conditions
Interventions
Intervention 1: Intervention Group:
Through this phase, clinical trial with two parallel RCT will be done. In this purpose, HIV-1/HSV-2 co-infected patients will be divided in two groups, 45 particip
Treatment - Drugs
Intervention Group:
Through this phase, clinical trial with two parallel RCT will be done. In this purpose, HIV-1/HSV-2 co-infected patients will be divided in two groups, 45 participants in each gr
Control Group:
45 HIV HSV2 positive participants will be recruit in this phase as control group ,
there is no drug treatment or intervention for this group.
After 1 year from the study baseline w
Sponsors
Resaerch Deputy tehran university of medical sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criterion: HIV positive patients referred to Iranian Research Center for HIV/AIDS-Imam Khomeini Hospital with CD4 count of 400-900 cells/mm3 and not being under antiviral therapy. Exclusion criteria: CD4 count above 400-900 cells/mm3; co infected with either HBV or HCV; having genital wart.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD4 Count. Timepoint: 1 year after intervention and starting for treatment. Method of measurement: Blood Test.;Viral Load. Timepoint: 1 year after intervention and starting for treatment. Method of measurement: Blood Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV progression. Timepoint: 1 year after starting the project. Method of measurement: lab tests and physical exams. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMinoo Mohraz MD
Iranian research Center for HIV AIDS (IRCHA)
Outcome results
None listed